Gilead Sciences (NASDAQ:GILD) Q1 2024 Results
Main financial results
-
Revenue: USD 6.69 billion (up 5.3% from Q1 2023).
-
Net loss: USD 4.17 billion (down from profit of USD 1.01 billion in Q1 2023).
-
Loss of USD 3.34 per share (down from profit of USD 0.81 in Q1 2023).
All numbers shown in the chart above are for the trailing 12 month (TTM) period.
Gilead Sciences' sales exceeded expectations, but EPS fell short
Sales exceeded analysts' expectations by 5.3%. Earnings per share (EPS) were 74% below analyst expectations.
Looking ahead, revenues are expected to grow at an average annual rate of 2.3% over the next three years, compared to a growth forecast of 18% for the U.S. biotech industry.
performance of American biotechnology industry.
The company's stock fell 2.0% from the previous week.
risk analysis
need to learn about. 4 warning signs We discovered this in collaboration with Gilead Sciences.
Have feedback on this article? Curious about its content? contact Please contact us directly. Alternatively, email our editorial team at Simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary using only unbiased methodologies, based on historical data and analyst forecasts, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.
